How can one optimize induction therapy in AML?-Reference-Cited by-同舟云学术

How can one optimize induction therapy in AML?

Published:2017-12 Issue:4 Volume:30 Page:301-305
ISSN:1521-6926
Container-title:Best Practice & Research Clinical Haematology
language:en
Short-container-title:Best Practice & Research Clinical Haematology

Author:

Luger Selina M.

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Oncology

Reference33 articles.

1. A comparative study of two regimens of combination chemotherapy in acute leukemia;Frei;Blood,1958

2. A randomized clinical trial of daunorubicin and a combination of prednisone, vincristine, 6-mercaptopurine, and methotrexate in adult acute nonlymphocytic leukemia;Wiernik;Cancer Res,1972

3. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia;Yates;Cancer Chemother Rep,1973

4. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B;Rai;Blood,1981

5. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study;Yates;Blood,1982

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expression analysis, clinical significance and potential function of PLXNB2 in acute myeloid leukaemia;Molecular Biology Reports;2023-08-26

2. Diagnosis and treatment of therapy-related acute myeloid leukemia;Critical Reviews in Oncology/Hematology;2022-03

3. Extracellular Vesicles in Acute Leukemia: A Mesmerizing Journey With a Focus on Transferred microRNAs;Frontiers in Cell and Developmental Biology;2021-10-06

4. A Proteomic Approach to Understand the Clinical Significance of Acute Myeloid Leukemia–Derived Extracellular Vesicles Reflecting Essential Characteristics of Leukemia;Molecular & Cellular Proteomics;2021

5. Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine;BMC Cancer;2020-10-12